Agenus (NASDAQ:AGEN) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a buy rating in a research note issued to investors on Monday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Agenus has a consensus rating of “Hold” and a consensus target price of $14.50.

Agenus Stock Performance

AGEN opened at $3.77 on Monday. The stock has a market capitalization of $144.76 million, a price-to-earnings ratio of -8.20 and a beta of 1.60. The company has a fifty day moving average of $3.22 and a 200 day moving average of $3.67. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.83. The company had revenue of $34.20 million during the quarter, compared to analysts’ expectations of $28.10 million. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. On average, equities research analysts forecast that Agenus will post -12.55 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

A number of institutional investors and hedge funds have recently made changes to their positions in AGEN. EP Wealth Advisors LLC purchased a new position in shares of Agenus in the 4th quarter worth $31,000. R Squared Ltd purchased a new position in shares of Agenus in the 4th quarter worth $41,000. Redwood Family Wealth LLC purchased a new position in shares of Agenus in the 4th quarter worth $44,000. Traynor Capital Management Inc. purchased a new position in shares of Agenus in the 3rd quarter worth $50,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Agenus in the 4th quarter worth $54,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.